| DB ID | MyCo_3539 |
| Title | Evaluation of biomarkers: Galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre |
| Year | 2018 |
| PMID | 30880706 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Immunocompromised Patients from a Tertiary Care Centre |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | Since the study was retrospective in design and the patients were not subjected to any intervention apart from the standard of care, ethical clearance was not required. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | India |
| Cohort | We conducted a retrospective study from January 2016 to December 2016, including immunocompromised patients with clinical suspicion of IFI. These comprised of patients with haematological malignancies, immunosuppression following solid organ or stem cell transplantation and patients with inherited or acquired immunodeficiency. A total of 70 consecutive patients were included, of which 41 had IFI (10 proven and 31 probable) while 29 had no IFI. |
| Cohort No. | 70 |
| Age Group | 5–72 |
| P Value | None |
| Sensitivity | 0.974 |
| Specificity | 0.966 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Despite the advent of new antifungal agents, invasive fungal infections (IFIs) continue to remain a major cause of concern in immunocompromised patients due to high morbidity and mortality. Rapid and accurate diagnosis of IFI is essential, but challenging due to non specific clinical radiological findings, need for invasive sampling and a low sensitivity of conventional culture and histopathology techniques. Prompt recognition and treatment of life threatening IFIs in patients with immunosuppression such as those with haemato oncological malignancies, congenital or acquired immunodeficiencies, transplant recipients and immunosuppressive medication are crucial for improved outcomes. |
| Technique | Assay |
| Analysis Method | Fungitell assay |
| ELISA kits | Platelia Aspergillus Ag kit (Bio‑Rad laboratories, WA, USA) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
